Clinical Liver Disease
© 2014 The American Association for the Study of Liver Diseases
Recently Published Issues
Current Issue:July 2014
Volume 4, Issue 1
Special Issue: Drug-Induced Liver Injury (DILI)
Volume 3, Issue 6
Special Issue: Vascular Disorders
Volume 3, Issue 5
Special Issue: Heavy Metals and the Liver
Volume 3, Issue 4
Special Issue: Autoimmune Liver Disease, Part 4
Volume 3, Issue 3
Special Issue: Autoimmune Liver Disease, Part 3
Drug-Induced Liver Injury (DILI)
Guest Edited by: Robert J. Fontana, M.D.
Herbal and Dietary Supplement Hepatotoxicity
Vinaya C. Maddukuri, M.D., and Herbert L. Bonkovsky, M.D.
Herbal and dietary supplements (HDS) include vitamins, minerals, herbs or other plant materials, and some can cause hepatotoxicity. HDS hepatotoxicity has risen almost threefold over the past decade, read more to learn what clinicians need to look for.
Causality Assessment: Which Is Best—Expert Opinion or RUCAM?
James H. Lewis, M.D.
Causality assessment for DILI began more as an art form than a science, and while methods have improved, there is still often an element of "guilt by association." Dr. James Lewis reviews the benefits and limitations of DILI causality assessment.
Incidence and Outcomes of DILI in Western Patients
Einar S. Bjornsson, M.D., Ph.D.
In its most severe form, DILI can lead to acute liver failure with associated mortality and need for liver transplantation. While most previous cohort studies have been retrospective and likely underestimate this difficult-to-diagnose adverse drug reaction, findings from more recent research are providing new insight into the etiologies and outcomes of DILI in Western countries.
Liver Histology in the Diagnosis and Prognosis of Drug-Induced Liver Injury
David E. Kleiner, M.D., Ph.D.
Unlike with some other more prevalent liver diseases, there is no clearly defined role or professional guidelines for the use of liver biopsy in DILI, presenting unique challenges to the clinician as well as the pathologist. Dr. Kleiner reviews pattern of injury, severity, and prognosis through biopsy evaluation.
LiverTox: An Online Information Resource and a Site for Case Report Submission on Drug-Induced Liver Injury
Jose Serrano M.D., Ph.D.
As a part of a long-term initiative in promoting basic and clinical research on DILI, the Liver Disease Research Branch of the NIDDK—in collaboration with the National Library of Medicine (NLM) and the DILIN—has created the LiverTox website www.livertox.gov to provide up-to-date, comprehensive clinical information on DILI for both health care providers and the public.
Series on New Treatments for Hepatitis C
Guest Edited by Donald M. Jensen, M.D., F.A.C.P.
New All-Oral HCV Therapies for Genotype 1: A Final Good-bye to Interferon
Anna S.F. Lok, M.D.
With more than 30 direct-acting antiviral agents (DAAs) in clinical trials, the hepatitis C community anticipates that the right combinations of DAAs will emerge, permitting treatment of hepatitis C virus (HCV) genotype 1 with interferon (IFN)-free regimens.
New AASLD/IDSA HCV Practice Guidelines: An Online Resource
Gary L. Davis, M.D.
As treatment for Hepatitis C rapidly evolves, how are recommendations being developed, and how they will be updated over time? Read or listen to Dr. Gary Davis' review to learn more about how organiziations like the AASLD are working to keep clinicians informed with the best and most up-to-date guidelines.
Recent FDA Approval of Sofosbuvir and Simeprevir. Implications for Current HCV Treatment
M. Valerie Lin, M.D., and Raymond Chung, M.D.
Drs. Lin and Chung break down what clinicians need to know about Sofosbuvir and Simeprevir: from mechanisms of action, to approved indications, use outside approved indications, and treatment challenges.
Test your knowledge! Use the Hepatitis C Self Assessment to complete board-style practice questions.
More from Drug-Induced Liver Injury (DILI)
Acetaminophen Overdose: What Practitioners Need to Know
Khurram Bari, M.D., and Robert J. Fontana, M.D.
Acetaminophen overdose is the most common cause of drug-induced liver injury in the United States, with about 60,000 cases reported each year, and also accounts for nearly 50% of adult acute liver failure (ALF) cases. Learn about epidemiology, clinical presentation, treatment, prognosis, and steps being taken to prevent overdose.
Overview of Drug-Induced Liver Injury in China
Gui-Qiang Wang, M.D., Yong-Qiong Deng, M.D., and Feng-Qin Hou, M.S.
Differences in the underlying diseases and disorders in Eastern populations compared to Western populations, as well as the frequent use of traditional Chinese medicine, mean that the epidemiology and etiologies of DILI may differ in China compared to other parts of the world. Learn from experts in the region about the epidemiology, etiologies, and management of DILI in mainland China.
Access CLD on the go.
Listen to the author interviews and readings of the full articles by subscribing to the iTunes podcast.